Vanguard Group Inc. Cuts Holdings in Integra LifeSciences Holdings Corporation $IART

Vanguard Group Inc. reduced its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 0.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,516,628 shares of the life sciences company’s stock after selling 64,339 shares during the quarter. Vanguard Group Inc. owned about 9.73% of Integra LifeSciences worth $165,291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in IART. LPL Financial LLC purchased a new position in shares of Integra LifeSciences in the 4th quarter worth $255,000. Raymond James Financial Inc. purchased a new position in shares of Integra LifeSciences in the 4th quarter worth $943,000. Sterling Capital Management LLC boosted its position in Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 1,931 shares during the period. First Trust Advisors LP boosted its position in Integra LifeSciences by 319.7% during the 4th quarter. First Trust Advisors LP now owns 186,300 shares of the life sciences company’s stock worth $4,225,000 after purchasing an additional 141,907 shares during the period. Finally, MetLife Investment Management LLC boosted its position in Integra LifeSciences by 5.3% during the 4th quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company’s stock worth $947,000 after purchasing an additional 2,111 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $14.26 on Thursday. Integra LifeSciences Holdings Corporation has a 12-month low of $11.06 and a 12-month high of $27.13. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.18, a price-to-earnings-growth ratio of 0.83 and a beta of 1.16. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The firm’s fifty day moving average price is $12.70 and its 200 day moving average price is $16.62.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same quarter in the previous year, the firm posted $0.63 EPS. The firm’s quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IART. JPMorgan Chase & Co. decreased their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. JMP Securities decreased their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday, May 9th. Finally, Wells Fargo & Company decreased their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and a consensus price target of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.